Cell surface sialic acid inhibits Cx43 gap junction functions in constructed Hela cancer cells involving in sialylated N-cadherin.
Numerous studies have shown that changes in the glycan structures of cells correlate with tumorigenesis, however, a casual link between the altered glycan structures and the abnormal GJIC in cancer cells is rarely studied. In this paper, we investigated the effects of sialic acid on the Cx43 gap junction functions, and clarified its potential mechanisms thereby. Sialidase significantly increased Cx43 gap junction functions in constructed Cx43-Hela cells along with down-regulation of cell surface sialic acid, which is dramatically reversed by sialidase inhibitor NeuAc2en. Further study indicated that sialidase failed to affect Cx43 at either protein or phosphorylation level, instead, it induced a considerable fraction of Triton X-100 insoluble, as compared with the untreated cells. We also found that sialidase treatment reduced the N-cadherin glycosylation and enhanced both Cx43-ZO-1 interaction and N-cadherin-ZO-1 association. Moreover, sialidase promoted the cell-cell adhesion with elevating N-cadherin binding to β-catenin, accompanied by increasing colocalization of Cx43 with microtubules at the cell periphery. Based on live cell microscopy, with the FARP technology in the Cx43-EGFP-Hela cells, we found that Cx43 in the plague recovered more quickly in sialidase treatment group, indicating that sialidase could promote the Cx43 traffic to the plague. Overall, these studies indicate cell surface sialic acid on cancer cells may suppress Cx43 gap junction functions via inhibiting Cx43 traffic to the plague involving in sialylated N-cadherin, a process that likely underlies the intimate association between abnormal GJIC and glycosylation on cancer development.
Li
Jing
J
Department of Pharmacology and Glycobiology, School of Medicine and Pharmacy, Ocean University of China, Qingdao, People's Republic of China.
Cheng
Lei
L
Wang
Li-juan
LJ
Liu
Hong-chun
HC
Li
Li
L
Wang
Xiao-lu
XL
Geng
Mei-yu
MY
D015153:Blotting, Western; D015820:Cadherins / Q000378:metabolism*; D002462:Cell Membrane / Q000378:metabolism; D018031:Connexin 43 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D005434:Flow Cytometry; D006367:HeLa Cells; D006801:Humans; D019158:N-Acetylneuraminic Acid / Q000378:metabolism*
D015820:Cadherins; D018031:Connexin 43; D019158:N-Acetylneuraminic Acid
Arch Biochem Biophys. 2000 Dec 15;384(2):205-15
11368307
Semin Cell Dev Biol. 2004 Dec;15(6):657-63
15561585
Physiol Rev. 2003 Oct;83(4):1359-400
14506308
Biochimie. 2004 Apr-May;86(4-5):241-4
15194225
J Cell Biol. 1997 Jul 14;138(1):181-92
9214391
Biochimie. 2001 Jul;83(7):623-34
11522391
FEBS Lett. 1992 Aug 3;307(3):361-6
1379545
Annu Rev Biochem. 1996;65:475-502
8811187
Curr Biol. 1998 Jul 30-Aug 13;8(16):931-4
9707407
Curr Drug Targets. 2002 Dec;3(6):465-82
12448698
Mol Biol Cell. 2005 Dec;16(12):5686-98
16195341
Bone. 2007 Jul;41(1):77-86
17512814
Adv Cardiol. 2006;42:41-56
16646583
J Cell Biol. 1991 Dec;115(5):1357-74
1659577
Front Biosci. 1998 Feb 15;3:d208-36
9458335
J Biol Chem. 2003 May 9;278(19):17269-76
12604612
Cell Commun Signal. 2009 Mar 12;7:4
19284610
J Cell Biol. 2003 Nov 10;163(3):525-34
14610055
Cancer Sci. 2008 Jul;99(7):1304-10
18492092
Cell. 2007 Feb 9;128(3):547-60
17289573
Biochem J. 1991 Jan 1;273(Pt 1):67-72
1846532
J Biochem Biophys Methods. 1991 Jan;22(1):23-33
1706371
Biol Cell. 2002 Nov;94(7-8):493-500
12566222
J Biol Chem. 1995 Nov 3;270(44):26581-5
7592880
J Biol Chem. 1990 Feb 15;265(5):2923-8
2154466
J Biol Chem. 1979 Mar 25;254(6):2138-47
422573
J Cell Biol. 1990 Nov;111(5 Pt 1):2077-88
2172261
J Bone Miner Res. 2008 Mar;23(3):350-60
17997713
J Biol Chem. 2005 May 20;280(20):19925-36
15741167
Acta Biochim Pol. 2002;49(4):991-8
12545205
Carcinogenesis. 2001 Sep;22(9):1537-42
11532877
Methods. 2000 Feb;20(2):245-64
10671317